SCHEMBL1819248

SCHEMBL1819248

O=C(O)[C@@H]1CCCN1Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.60
CYP2C19 P33261 1/20 0.59
NPSR1 Q6W5P4 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
SPHK1 Q9NYA1 1/20 0.56
CCR4 P51679 1/20 0.52
GRM6 O15303 1/20 0.51
CD274 Q9NZQ7 7/20 0.51
PDCD1 Q15116 2/20 0.51
OPRL1 P41146 2/20 0.49
OPRM1 P35372 1/20 0.49
OPRK1 P41145 1/20 0.49
MCHR1 Q99705 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1972076 1.00 CYP1A2 (0.60) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
SCHEMBL2587055 1.00 CYP1A2 (0.60) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL992441 0.98 CYP1A2 (0.59) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL20790624 0.98 CYP1A2 (0.59) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL992443 0.98 CYP1A2 (0.59) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
SCHEMBL3713831 0.95 SMN1; SMN2 (0.63) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
SCHEMBL16714062 0.95 SMN1; SMN2 (0.63) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
SCHEMBL3713829 0.95 SMN1; SMN2 (0.63) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL2500262 0.94 SMN1; SMN2 (0.61) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1
Hydrochloric Acid SCHEMBL7742897 0.94 SMN1; SMN2 (0.61) CYP1A2CYP2C19NPSR1SMN1; SMN2SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121574104-A Preparation method, condensing agent and application of cosmetic peptide prolyl-lysine 天津卡普希科技有限公司 2026-02-27 CN claimed
US-20250361490-A1 COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA CELLVIE AG (CH) 2025-11-27 US claimed
EP-4535996-A1 COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA cellvie AG (CH) 2025-04-16 EP claimed
CN-119365073-A Compositions and methods for cryopreserving mitochondria 赛立维公司 2025-01-24 CN claimed
WO-2023237789-A1 COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA CELLVIE AG (CH) 2023-12-14 WO claimed
CN-113207899-A Fine glufosinate-diuron compounded weeding composition, preparation method and application thereof 安徽喜田生物科技有限公司 2021-08-06 CN claimed
CN-104098650-B The synthesis and application of the intermediate of Atosiban 中国医学科学院药物研究所 2019-04-09 CN claimed
WO-2017029408-A1 SOLID STATE FORMS OF SOFOSBUVIR RATIOPHARM GMBH (DE) 2017-02-23 WO claimed
US-20150353619-A1 Non-Canonical Insulins and Their Uses CALIFORNIA INSTITUTE OF TECHNOLOGY 2015-12-10 US claimed
EP-2334324-A2 BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY Fibrex Medical Research & Development GmbH (AT) 2011-06-22 EP claimed
WO-2010043972-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-22 WO claimed
US-20080108830-A1 Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound AJINOMOTO CO. INC (JP) 2008-05-08 US claimed
EP-1918276-A1 Production method of optically active 2- [ (N-Benzylprolyl) Amino ] Benzophenone compound Ajinomoto Co., Inc. (JP) 2008-05-07 EP claimed
WO-2005085178-A1 METHOD OF PREPARING OPTICALLY ACTIVE SERINE DERIVATIVE ESTECHPHARMA CO., LTD. (KR) 2005-09-15 WO claimed
US-20260117001-A1 FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF ERISYON INC (US) 2026-04-30 US disclosed
CN-121574104-A Preparation method, condensing agent and application of cosmetic peptide prolyl-lysine 天津卡普希科技有限公司 2026-02-27 CN disclosed
US-20250361490-A1 COMPOSITION AND METHOD FOR CRYOPRESERVATION OF MITOCHONDRIA CELLVIE AG (CH) 2025-11-27 US disclosed
US-4386075-A IMPROVING KIDNEY FUNCTION SMITHKLINE BECKMAN CORPORATION (US) 1983-05-31 US disclosed
US-3985732-A ANXIOLYTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1976-10-12 US disclosed
US-3968298-A Process for imparting to natural keratin-containing material a permanent finish rendering the material resistant to damage by insects CIBA-GEIGY CORPORATION (US) 1976-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353619-A1 Non-Canonical Insulins and Their Uses IAPP, IDE, INSR CYP1A2 2895/4885CYP2C19 258/4885NPSR1 278/4885
US-20080108830-A1 Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound NPEPPS, SYMPK, REN CYP1A2 992/4885CYP2C19 458/4885NPSR1 2415/4885
US-20260117001-A1 FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF QPCTL, QRFPR, CD47 CYP1A2 4788/4885CYP2C19 4339/4885NPSR1 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.